From Biomarker to Mechanism? F2-isoprostanes in Pulmonary Fibrosis

被引：4
|
作者：
Thatcher, Thomas H. [1 ]
Peters-Golden, Marc [2 ]
机构：
[1] Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA 23284 USA
[2] Univ Michigan, Med Sch, Dept Internal Med, Ann Arbor, MI USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2022年 / 206卷 / 05期
关键词：
THROMBOXANE A(2); RECEPTOR;
D O I：
10.1164/rccm.202205-0914ED
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：530 / 532
页数：4
相关论文
共 50 条
  • [1] F2-isoprostanes affect macrophage migration and CSF-1 signalling
    Proudfoot, J. M.
    Murrey, M. W.
    McLean, S.
    Greenland, E. L.
    Barden, A. E.
    Croft, K. D.
    Galano, J-M
    Durand, T.
    Mori, T. A.
    Pixley, F. J.
    FREE RADICAL BIOLOGY AND MEDICINE, 2018, 126 : 142 - 152
  • [2] Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis
    Collard, Harold R.
    Calfee, Carolyn S.
    Wolters, Paul J.
    Song, Jin Woo
    Hong, Sang-Bum
    Brady, Sandra
    Ishizaka, Akitoshi
    Jones, Kirk D.
    King, Talmadge E., Jr.
    Matthay, Michael A.
    Kim, Dong Soon
    AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2010, 299 (01) : L3 - L7
  • [3] Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis
    Xie, Yan
    Jiang, Haihong
    Zhang, Qian
    Mehrotra, Suneet
    Abel, Peter W.
    Toews, Myron L.
    Wolff, Dennis W.
    Rennard, Stephen
    Panettieri, Reynold A., Jr.
    Casale, Thomas B.
    Tu, Yaping
    RESPIRATORY RESEARCH, 2016, 17
  • [4] GDF15 is an epithelial-derived biomarker of idiopathic pulmonary fibrosis
    Zhang, Yingze
    Jiang, Mao
    Nouraie, Mehdi
    Roth, Mark G.
    Tabib, Tracy
    Winters, Spencer
    Chen, Xiaoping
    Sembrat, John
    Chu, Yanxia
    Cardenes, Nayra
    Tuder, Rubin M.
    Herzog, Erica L.
    Ryu, Changwan
    Rojas, Mauricio
    Lafyatis, Robert
    Gibson, Kevin F.
    McDyer, John F.
    Kass, Daniel J.
    Alder, Jonathan K.
    AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2019, 317 (04) : L510 - L521
  • [5] S100A12 as Biomarker of Disease Severity and Prognosis in Patients With Idiopathic Pulmonary Fibrosis
    Li, Yupeng
    He, Yaowu
    Chen, Shibin
    Wang, Qi
    Yang, Yi
    Shen, Danting
    Ma, Jing
    Wen, Zhe
    Ning, Shangwei
    Chen, Hong
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [6] Prostaglandin E2 and the Pathogenesis of Pulmonary Fibrosis
    Bozyk, Paul D.
    Moore, Bethany B.
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2011, 45 (03) : 445 - 452
  • [7] Pharmacological mechanism of Astragalus and Angelica in the treatment of idiopathic pulmonary fibrosis based on network pharmacology
    Zhang, Yufeng
    Jiang, Weilong
    Xia, Qingqing
    Qi, Jia
    Cao, Mengshu
    EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE, 2019, 32
  • [8] Modulation of pulmonary fibrosis by IL-13Rα2
    Lumsden, Robert V.
    Worrell, Julie C.
    Boylan, Denise
    Walsh, Sinead M.
    Cramton, Jennifer
    Counihan, Ian
    O'Beirne, Sarah
    Medina, Maria Fe
    Gauldie, Jack
    Fabre, Aurelie
    Donnelly, Seamas C.
    Kane, Rosemary
    Keane, Michael P.
    AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2015, 308 (07) : L710 - L718
  • [9] Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis - a potential biomarker role for LysoPC
    Rindlisbacher, Barbara
    Schmid, Cornelia
    Geiser, Thomas
    Bovet, Cedric
    Funke-Chambour, Manuela
    RESPIRATORY RESEARCH, 2018, 19
  • [10] Potential Mechanism Prediction of Herbal Medicine for Pulmonary Fibrosis Associated with SARS-CoV-2 Infection Based on Network Analysis and Molecular Docking
    Jin, De
    An, Xuedong
    Zhang, Yuqing
    Zhao, Shenghui
    Duan, Liyun
    Duan, Yingying
    Lian, Fengmei
    Tong, Xiaolin
    FRONTIERS IN PHARMACOLOGY, 2021, 12
12345